|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.305 USD | -3.33% |
|
+4.40% | -63.03% |
| 06-30 | ADC Therapeutics SA Completes Enrollment In LOTIS-7 Phase 1b ZYNLONTA Combination Trial | CI |
| 06-30 | ADC Therapeutics Completes Enrollment in LOTIS-7 Lymphoma Study | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| ADC THERAPEUTICS SA | Bio Therapeutic Drugs | -3.70% | +4.40% | -63.03% | -58.44% | -94.21% | 172M |  |  | |
- Stock Market
- Stocks
- ADCT Stock
- Charts ADC Therapeutics SA
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
